MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Molecular Partners AG - American Depositary Shares (NQ:MOLN)

4.200 +4.200 (+1049875.00%)
Streaming Delayed Price Updated: 12:16 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Molecular Partners AG - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2024
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Dismissal of Class Action Lawsuit
From Molecular Partners
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
From Molecular Partners
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2023
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
From Molecular Partners
Via GlobeNewswire
News headline image
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
Via MarketBeat
Topics Initial Public Offering
News headline image
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
From Molecular Partners
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story